rebound eingeläutet!??
Brauche nur auf mein Depot zu gucken.
Vielleicht sind meine Leichen bald wieder was Wert?
http://finance.yahoo.com/news/...illion-impact-by-2020-133004729.html
Optionen
| Boardmail an "prego" |
Wertpapier: Cannabis Science |
Optionen
| Boardmail an "prego" |
Wertpapier: Cannabis Science |
Company counsel is determining the qualifying criteria for both electronic and physical certificate holders. For example, the evidence of ownership may include brokerage statements with timestamps and share balances that can be checked against Company records. These criteria will likely include proof of when a stock certificate was received, a copy of any stock power or certificate itself, as well as evidence of any assignments and conversions.
Once processing requirements are finalized and announced, shareholders will have 90 days to return the requested documents to Cannabis Science. The Company is researching the most efficient documentation procedure for formal verification and future share gifting, including the methods of receiving shareholder information, such as by email, direct mail, and/or facsimile. The Company is also considering whether this information should be provided directly to the Company or to its transfer agent.
"The March 31, 2016 date is designed to encompass all shareholders, old & new, as well as to distinguish those who have been loyal, patient, and persistent with us over the years, as they deserve special recognition. Concurrently, we are laser focused on the execution of our operations that involve so many tremendous opportunities," said Raymond C. Dabney, CBIS President & CEO, Co-Founder. Mr. Dabney continued, "I am so happy to personally 'reward' our investors, so to speak, by gifting them my own shares. As we enter the next phase of the Company's development, the timing of this shareholder 'thank you' is perfect."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
News von der cbis seite
Optionen
| Boardmail an "famherzig" |
Wertpapier: Cannabis Science |
http://www.microcapdaily.com/...nabis-science-inc-otcmktscbis/115133/
https://translate.google.de/...nc-otcmktscbis/115133/&prev=search
- Cannabis Science Inc.'s stock edged higher by 48.11% to close Monday's session at USD 0.016. The company's shares oscillated between USD 0.010 and USD 0.019. The stock recorded a trading volume of 117.91 million shares, which was much above its 50-day daily average volume of 10.92 million shares and its 52-week average volume of 6.81 million shares. Over the last three days Cannabis Science Inc.'s shares have advanced 36.52% and in the past one week the stock has moved up 46.73%. However, over the last three months the stock has lost 4.85% and in the past six months the shares have shed 55.14%. On a compounded total return basis, the company has returned 19.85% in the past one month. Additionally, the stock is trading at a price to sales ratio of 183.81.
Die letzten Zahlen seitens Cannabis Science vom 24.11.2015 wurden hier sicherlich bereits kritisch beäugt, oder?
http://yahoo.brand.edgar-online.com/default.aspx?cik=1024626
Anfang April vermutlich die neuen Zahlen. Und da wird dann Tacheles geredet, denke ich mal. Strategische Kursentwicklung nicht unterschätzen... ;-)
Sicherlich sind auch dicke Gewinne drin. Aber trotzdem vorsichtig sein.
Bei mir ist es zwar nur ein wenig Spielgeld aber erst bei 0,15 Euro fange
ich an zu lächeln.
Optionen
| Boardmail an "prego" |
Wertpapier: Cannabis Science |
Moderation
Zeitpunkt: 27.04.16 13:07
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Werbe-ID.
Zeitpunkt: 27.04.16 13:07
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Werbe-ID.
COLORADO SPRINGS, CO -- (Marketwired) -- 04/18/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to extend its congratulations to the State of Pennsylvania as the 24th state to legalize cannabis for medical purposes.
On Sunday, April 17, 2016, the Governor of Pennsylvania signed into law Senate Bill 3, legalizing medical cannabis consumption. Pennsylvania represents the 24th state to pass such legislation. The U.S. is nearly halfway to full medical legalization. As more states legalize medical cannabis, research and clinical trials can become simpler and less expensive to initiate and maintain.
"While we don't currently have operations in Pennsylvania, we are certainly expecting a few calls to come in. We are excited to have the option to explore potential partnerships and research opportunities there in the future," said Director, President, CEO & Co-Founder, Raymond C. Dabney. "On behalf of our company and the medical cannabis industry as a whole, we would like to extend a warm welcome to the new patients that the SB3 bill will benefit."
The bill received 149 votes in favor and 46 votes opposing legalizing medical cannabis in a Republican-controlled House. The landslide victory on this bill shows even many of the more conservative politicians are opening their minds to the potential lifesaving properties of cannabis as another viable medical treatmen.
Link: http://www.finanznachrichten.de/...-legalize-medical-cannabis-256.htm
Optionen
| Boardmail an "Kampfschwein300" |
Wertpapier: Cannabis Science |
COLORADO SPRINGS, CO -- (Marketwired) -- 05/04/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to publicly applaud the Drug Enforcement Agency (DEA) for their latest decision to green light clinical trials on the effectiveness of smoked marijuana as a treatment option for post-traumatic stress disorder, proposed Harborside resolution, and the re-scheduling for mass access to expanded treatments. These recent moves by the DEA seem to be signaling the signs of changing times, the right Industry at the right time.
Cannabis Science believes this is it and the Company is very well positioned to move into mass expansion mode as new projects and current drug development initiatives get underway and move forward with exponential growth and sharply increased value.
Fortune Story on MAPS PTSD Study approved by the DEA:
The DEA green-lit a clinical trial of smoked marijuana for the treatment of post-traumatic stress disorder (PTSD) in American military veterans, a spokesperson for the government agency confirmed to Fortune. While other trials have studied the medical benefits of marijuana and cannabis extracts like cannabidiol, this is the first time regulators have allowed testing of the marijuana plant itself for the purpose of developing it into a legal medical drug.
The Multidisciplinary Association for Psychedelic Studies (MAPS), an organization researching legal uses for marijuana and other mind-altering drugs, is conducting the trial, which is funded by a $2.2 million grant from Colorado's state health department. MAPS had worked for more than five years to obtain clearance from regulators to use pot in the trial; while it received the OK from the U.S. Food and Drug Administration in 2011 and from the U.S. Public Health Service in 2014, it still had to wait for the DEA's approval in order to proceed.
http://fortune.com/2016/04/22/dea-medical-marijuana/?iid=sr-link1
Harborside story from the SFGATE:
In a milestone victory for the cannabis industry, the federal government agreed to drop its four-year bid to shut down Oakland's Harborside Health Center, the biggest medical marijuana dispensary in the country with more than 100,000 patients, city leaders said Tuesday.
The Department of Justice did not immediately comment on the deal, which Harborside said still needed to be finalized, with all of the parties in the legal fight signing off.
But Oakland officials joined the pot dispensary in an exultant news conference at City Hall, heralding a move they saw as symbolic of a federal withdrawal in the battle against an industry that is steadily marching toward acceptance -- and is viewed in Oakland not as a scourge but an economic engine.
"We celebrate the release from federal prosecution," said Mayor Libby Schaaf. "We believe in compassion, we believe in health."
http://www.sfgate.com/bayarea/article/...rside-in-big-win-7390365.php
The DEA has recently become more open to the benefits and plausibility of medical marijuana as a treatment option. In addition to green lighting this new trial, Harborside resolution, and of course with the agency recently announcing their intention to review the scheduling of marijuana as a drug within the first half of 2016. This is a great sign of progress for the agency.
"Can this be it? Will we see it sooner than later? We are so excited to be part of this industry as the federal government is starting to review antiquated policies, which have long acted as roadblocks to people seeking natural treatment options and Companies moving forward with viable treatment options for the people. I believe this is it. We are ready with all our formulations in place and new complex underway; we are certainly ready to rise to the occasion!" said Cannabis Science, Inc. CEO Raymond C. Dabney.
As federal and state policies loosen, companies like Cannabis Science will be able to perform studies, conduct trials, and roll out products much faster and more affordably. This progress is critical for companies to continue bringing more effective and affordable, natural treatments to patients across the country.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Optionen
| Boardmail an "Kampfschwein300" |
Wertpapier: Cannabis Science |
CAPE TOWN, SOUTH AFRICA -- (Marketwired) -- 05/23/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces arrival of a Cannabis Science delegation beginning in Cape Town, South Africa to launch a historic Africa Healthcare initiative led by President & CEO, Co-Founder Raymond C. Dabney.
Mr. Dabney is accompanied by Dr. Allen A. Herman, the Chief Medical Officer (CMO) of CBIS, Mr. Melvin P. Foote, President and Executive Director of Constituency for Africa (CFA), and Dr. Julius Garvey, surgeon and noted advocate for African healthcare and a member of the Scientific Advisory Board (SAB) of CBIS.
Beginning in Cape Town, South Africa, the CBIS delegation is here to meet with key stakeholders in government, the private sector, civil society, and academia. The delegation will then move forward to other countries and major cities in the continent. CBIS is dedicated to collaboration with international regulatory agencies in South Africa and other African countries to provide access to high quality, first-class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions.
CBIS products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. By establishing operations in Southern Africa to develop and supply pharmaceuticals throughout the African continent, CBIS intends to access an underserved market with a total population of over 1.1 billion people. Through Public Private Partnerships in Southern Africa, the Company believes it can bring new products to market and increase company revenues, all while contributing to economic development in Africa through job creation, capacity building, and technology transfer.
The Government and the educational and research leaders of South Africa continues its leadership in its development and implementation of initiatives to strengthen the country's health-care infrastructure and improve the delivery of health-care education and services to the South African people. Given this, we believe that South Africa and other African countries have indicated interest and are perceived to be ideal potential partners for CBIS as we explore opportunities to establish educational and pharmaceutical development operations in Sub-Saharan Africa.
The delegation will also discuss the critical role that the Raymond C. Dabney University (RCDU) will play in the development of cannabinoid and other plant-based pharmaceuticals across the continent. RCDU is developing partnerships with universities in the United States and these partnerships will expand education and training opportunities in law and healthcare to members of disadvantaged communities and populations, and provide intellectual and laboratory resources for pharmaceutical development. The delegation will discuss the expansion of this model partnership to include African governments across the continent including educational and research institutions.
The company believes that at the heart of its drug development program there is a broader development objective that will improve the capacities of government, educational and research partners in across the continent of Africa.
The discussions will explore three main areas:
1. The legislative and regulatory environment that governs the growth of cannabis and the development of approved medicines based on the cannabis plant. We will meet with and discuss this with government ministers of health and agriculture. Additionally, we will explore the processes required by the Medicines Control Councils (the FDA equivalent agencies) of African countries to establish drug development programs.
2. What partnerships with educational, research, and community organizations will be necessary for effective drug development programs?
3. What are the education and training needs of our potential African country partners?
"I am very excited to arrive on the African continent for my very first visit," said Mr. Dabney, "and I look forward to developing sustainable partnerships with the governments and people of Africa."
Mr. Melvin P. Foote, President and Executive Director of Constituency for Africa (CFA), said, "At the heart of this visit is the creation of a drug development program that emphasizes local job creation, education and training. The Constituency for Africa joins CBIS in this venture because we believe that this program will develop sustainable job creation across a number of key sectors."
Dr. Allen A. Herman, the Chief Medical Officer (CMO) of CBIS, suggested, "Drug development programs, by their very nature, require well-trained sophisticated personnel and that this comprehensive CBIS program will create the intellectual and industrial infrastructure that will serve as a platform for plant-based pharmaceutical development across a wide range of local sources."
Link: http://www.finanznachrichten.de/...-ceo-co-founder-mr-raymond-256.htm
Optionen
| Boardmail an "Kampfschwein300" |
Wertpapier: Cannabis Science |